ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Fundamental Analysis
USA - NASDAQ:CYTO - BMG0360L1349 - Common Stock
0.3 USD
-0.11 (-25.94%)
0.262 USD
-0.04 (-12.67%)
Overall CYTO gets a fundamental rating of 3 out of 10. We evaluated CYTO against 191 industry peers in the Pharmaceuticals industry. While CYTO seems to be doing ok healthwise, there are quite some concerns on its profitability. CYTO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CYTO was profitable.
In the past year CYTO had a positive cash flow from operations.
In the past 5 years CYTO always reported negative net income.
CYTO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CYTO (-0.09%) is better than 82.20% of its industry peers.
CYTO has a better Return On Equity (-0.11%) than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| ROIC | N/A |
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYTO has more shares outstanding
The number of shares outstanding for CYTO has been increased compared to 5 years ago.
Compared to 1 year ago, CYTO has an improved debt to assets ratio.
2.2 Solvency
CYTO has an Altman-Z score of 1.19. This is a bad value and indicates that CYTO is not financially healthy and even has some risk of bankruptcy.
CYTO has a Altman-Z score of 1.19. This is in the better half of the industry: CYTO outperforms 60.21% of its industry peers.
CYTO has a debt to FCF ratio of 0.09. This is a very positive value and a sign of high solvency as it would only need 0.09 years to pay back of all of its debts.
CYTO has a better Debt to FCF ratio (0.09) than 96.86% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that CYTO is not too dependend on debt financing.
CYTO has a Debt to Equity ratio (0.05) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.09 | ||
| Altman-Z | 1.19 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
A Current Ratio of 0.43 indicates that CYTO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.43, CYTO is doing worse than 95.81% of the companies in the same industry.
CYTO has a Quick Ratio of 0.43. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
CYTO's Quick ratio of 0.43 is on the low side compared to the rest of the industry. CYTO is outperformed by 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 101.44% over the past year.
The Revenue for CYTO has decreased by -79.76% in the past year. This is quite bad
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -4.65% on average over the next years.
CYTO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 214.13% yearly.
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
CYTO is valuated cheaply with a Price/Earnings ratio of 0.36.
Based on the Price/Earnings ratio, CYTO is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.06, CYTO is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CYTO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.36 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CYTO indicates a rather cheap valuation: CYTO is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.25 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYTO's earnings are expected to decrease with -4.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
5. Dividend
5.1 Amount
CYTO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.3
-0.11 (-25.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.13%
Inst Owner Change0%
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap1.13M
Revenue(TTM)62.75K
Net Income(TTM)-7.24K
Analysts82.86
Price Target5.41 (1703.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)31.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.36 | ||
| Fwd PE | N/A | ||
| P/S | 18.07 | ||
| P/FCF | 0.25 | ||
| P/OCF | 0.25 | ||
| P/B | 0.18 | ||
| P/tB | 0.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.83
EY276.67%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)1.22
FCFY406.8%
OCF(TTM)1.22
OCFY406.8%
SpS0.02
BVpS1.67
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 7351.86% |
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.09 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 1.19 |
F-Score6
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)1981.94%
Cap/Depr(5y)5522.5%
Cap/Sales(3y)2080.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A
EBIT growth 1Y98.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.19%
OCF growth 3YN/A
OCF growth 5YN/A
ALTAMIRA THERAPEUTICS LTD / CYTO FAQ
What is the fundamental rating for CYTO stock?
ChartMill assigns a fundamental rating of 3 / 10 to CYTO.
What is the valuation status of ALTAMIRA THERAPEUTICS LTD (CYTO) stock?
ChartMill assigns a valuation rating of 4 / 10 to ALTAMIRA THERAPEUTICS LTD (CYTO). This can be considered as Fairly Valued.
How profitable is ALTAMIRA THERAPEUTICS LTD (CYTO) stock?
ALTAMIRA THERAPEUTICS LTD (CYTO) has a profitability rating of 2 / 10.
How financially healthy is ALTAMIRA THERAPEUTICS LTD?
The financial health rating of ALTAMIRA THERAPEUTICS LTD (CYTO) is 3 / 10.
What is the expected EPS growth for ALTAMIRA THERAPEUTICS LTD (CYTO) stock?
The Earnings per Share (EPS) of ALTAMIRA THERAPEUTICS LTD (CYTO) is expected to decline by -88.67% in the next year.